Loading the records…
Loading the records…
Its government footprint in one place: federal money, influence and market activity, each row linked to its source. Federal figures gathered Oct 25, 2026.
AI Brief · sourced from the records below
Federal obligations to Amgen Inc were $152.2M in contracts from Jul 2025 to Jun 2026.[1] The top agency for FY2026 was the Department of Health and Human Services with $126.0M in contracts.[7] Lobbying firms for Amgen include Acg Advocacy, Akin Gump Strauss Hauer & Feld, and others.[11] Revolving door lobbyists include Katherine Fleming Cotton, Paul Edattel, and Eric Bergren from Todd Strategy Group.[12][13][14] Insider trades include Khosla Rachna selling $1.6M, Miller Derek selling $2.2M, and Grygiel Nancy A. selling $1.7M.[21][22][23] Members of Congress trading Amgen stock include David Taylor, Sheldon Whitehouse, and Alan Armstrong.[24][26][27]
Written by AI only from the records on this page. Every sentence was checked by code against the records it cites: each figure, date and name has to appear in them, and a sentence that did not match was removed. No opinion, no prediction.
Amount: obligated to date on the contract, all years. Ranked by that amount among contracts with any action in the last 12 months. Counts only consolidated subsidiaries.
Amount: obligated to date. From the contracts in HillSignal's records tied to this ticker; the full list of contracts ending across government is on Recompetes.
Every post as the lobbyist listed it on the company's Senate LDA filings, one per line.
Lobbying firms working for this company also represent these foreign principals. These are separate engagements: the firm's foreign work is not done for this company.
BGR Government Affairs, LLC lobbies the federal government for Amgen Inc: 12 filings, 2023 to 2026, on health issues (for example, “Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen…”). Separately, it is registered as an agent of 11 foreign principals. In its latest six-month FARA report (to Nov 30, 2025) it reported $4,663,572 received from foreign principals.
317 filings, 2023 to 2026. Paid lobbying firms $13.8M. In-house lobbying spend $39.6M.
Firms: Acg Advocacy, Akin Gump Strauss Hauer & Feld, Alpine Group Partners, LLC., Amgen, Inc., Avenue Solutions, Bgr Government Affairs and 4 more
Issues: Budget/Appropriations, Copyright/Patent/Trademark, Economics/Economic Development, Government Issues, Health Issues, Immigration, Labor Issues/Antitrust/Workplace, Law Enforcement/Crime/Criminal Justice
Contacted: Senate, House Of Representatives, Health & Human Services, Dept Of (Hhs), Centers For Medicare And Medicaid Services (Cms), Treasury, Dept Of, Food & Drug Administration (Fda), Executive Office Of The President (Eop), Natl Economic Council (Nec)
From the company's Senate LDA filings. Firm fees and in-house spend are reported on different filings, so they are shown apart. Lobbying is legal and common; it shows what the company paid to be heard on, not what it got.
Open-market buys and sells from SEC Form 4 filings; grants and option exercises left out, and trades whose filed price failed our market check. A 10b5-1 plan is a trading schedule set in advance, so those sells say little about the insider's view. The plan box is on filings from April 2023 on.
Every record that names this company by ticker, newest first: awards, bills, executive actions, SEC filings, news and private raises. Patents are listed below.
From a narrow USPTO sample of recent grants in strategic technology areas, not a full patent database: a missing patent here is not proof there is none.
USAspending (prime contracts only; no subcontracts or classified work; defense contracts can arrive up to 90 days after signing), SEC EDGAR, Senate LDA, FEC, House and Senate disclosures, the Federal Register and the White House. Companies are tied to records by exact name, a verified alias or a subsidiary in the company's own Exhibit 21; a miss is better than a wrong link. A shared date is not proof of cause, and nothing here is investment advice.
Obligated means an agency committed the money to this company in that period (a signed contract action), as reported to USAspending. It is not a payment and not revenue: a contract can be funded for several years at once, and revenue is booked as the work is done. Some years can exceed revenue for that reason.
Prime contracts only, and only what is published. Work the company does as a subcontractor is not in these figures, and classified contracts are not published on USAspending at all. A low share can mean either. Contract values, ceilings and options are never added in.
Which units count: the USAspending recipient that is the company's SEC registrant; units of the company that USAspending's own records place under it (as parent, or in its family tree); and subsidiaries from the company's SEC Exhibit 21 that carry its name. Joint ventures, units now owned by someone else, and records that only share a name are held back. Both lists are below.
Earlier years count the units the company owns today. A unit we checked by hand (its USAspending parent is out of date) counts from the date the company bought it, or, where no filing gives that date, from the first date a filing shows the company owning it. Other units count for every year shown until their purchase dates are loaded.
Revenue bars are the company's own fiscal year from its 10-K, placed in the federal year it ends in; its fiscal year can end in a different month than the government's.
Fiscal year 2022 onward. Federal fiscal years run October to September; the company's own fiscal year may differ.
Held back: a matching name we could not tie to this company firmly enough. A miss is better than a wrong link.
Agents registered at this firm, not necessarily assigned to this specific client: William Viney, David J. Urban, Steven Pfrang, Frank Ahrens, Emma Vaughn, Terry, III, Sydney Lee
Akin, Gump, Strauss, Hauer & Feld, LLP lobbies the federal government for Amgen Inc: 12 filings, 2023 to 2026, on taxation/internal revenue code and health issues (for example, “Issues related to international tax.”). Separately, it is registered as an agent of 4 foreign principals. In its latest six-month FARA report (to Jun 30, 2025) it reported $6,322,192 received from foreign principals.
Agents registered at this firm, not necessarily assigned to this specific client: Shiva Aminian, Christopher Armstrong Treanor, Thomas Krueger, Reginald Babin, Ileana Ros-Lehtinen, Lauren Rubin
Miller Strategies, LLC lobbies the federal government for Amgen Inc: 12 filings, 2023 to 2026, on health issues, medicare/medicaid and immigration (for example, “Issues related to visas”). Separately, it is registered as an agent of 2 foreign principals. In its latest six-month FARA report (to Dec 31, 2025) it reported $62,500 received from foreign principals.
Agents registered at this firm, not necessarily assigned to this specific client: Jeffrey Miller, Stefan Passantino, Jonathan Hiler
Capitol Counsel, LLC lobbies the federal government for Amgen Inc: 12 filings, 2023 to 2026, on medicare/medicaid (for example, “Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues.”). Separately, it is registered as an agent of 1 foreign principal. No amount is stated in its latest six-month FARA report (to Nov 30, 2025).
Agents registered at this firm, not necessarily assigned to this specific client: Cameron Sterling, David Lee Bridges, George A. Sifakis, Jacob Gray Hartley, Nicholas Lyle Bouknight, Michael R. Pawlowski
The company's own PAC (linked by the connected organization on its FEC Form 1). Top candidates it gave to, all cycles we hold, from the candidates' own FEC reports; tracked candidates only, so not a complete total.
Connections to other companies, executives and members of Congress, from disclosed trades, shared officers and public filings, are part of Pro. See Pro